Shareholders enjoyed a pleasant surprise when lllumina Inc. (NASDAQ: ILMN) reported its fourth-quarter and full-year 2016 results three months ago. Increased revenue from sequencing consumables and microarrays helped the gene-sequencing leader.
Illumina announced its first-quarter 2017 results after the market closed on Tuesday. Did the good news continue for the company? Here are the highlights.